Creso expands team: set to tap budding LatAm & Canadian pot markets
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
ASX pot-stock, Creso Pharma (ASX:CPH) has announced its second piece of good news this week — its appointment of John Griese as chief operating officer for the Americas.
This comes at an auspicious time, with CPH furthering its expansion into the Americas.
CPH’s acquisition of Canadian medical cannabis producer, Mernova Medicinal Inc., was completed back in February this year. Construction of its 20,000 square foot medicinal cannabis growing facility is expected to be completed in the near future, with the licensing process now in its final phases.
Griese will oversee the completion of the Mernova Medicinal facility, the final phases of the Kunna S.A.S. transaction, and the proposed acquisition of a Colombian cultivation facility.
Once the cultivation operations are finalised, bringing CPH’s comprehensive product range to market in both Canada and Latin America will become a critical priority for the biotech junior.
Creso CEO, Dr Miri Halperin Wernli, said: “We are excited about John’s appointment as Creso’s new COO for the Americas. He is a highly technical, hands-on leader capable of developing strategy and implementing operations at the grass roots level. He also has extensive experience in the North American food and cannabis industries.”
“Canada is a key market for the cannabis industry and offers great opportunity for growth. The recent historic passing of the cannabis act for full adult-use legalisation is a further demonstration of the huge potential Canada offers for the uptake of our products, and we are optimistic about the future of the industry in this market.”
“John’s appointment will help establish our presence in Canada, providing Creso with the knowledge and expertise needed to continue to grow our presence in the region,” Halperin Wernli added.
Griese brings with him over 25 years of experience in sales, manufacturing and supply chain with some of the world’s most successful food companies. His previous roles include Frito-Lay (a division of Pepsico) as Head of Supply Chain for Canada, Nestle USA as Head of Supply Chain for a $4.5 billion frozen food division, and the Toronto-based Sofina Foods.
Griese commented: “I look forward to taking on my new role and to assist Creso to further establish and grow its already significant foothold in the Americas. Creso’s ambitions fit well with my skill set and my experience in the cannabis market in North America. Creso’s products are well suited to meet the growing demands of consumers in these countries.”
However, it is an early stage of this company’s development in these countries and if considering this stock for your portfolio, you should take all public information into account and seek professional financial advice.
A pair of growing markets
Of the broader thriving Latin American cannabis market, Colombia is one of the fastest-growing segments. Colombians spent US$86.3 million on cannabis in 2008, and consumption has grown at 15 per cent per year.
Colombia legalised medical cannabis in 2016, and in the following year mapped out a framework for cultivation, production and distribution (including exports), establishing quality and consistency standards for the rest of Latin America.
Once its acquisition of Kunna is finalised, CPH will be one of only a few companies globally — and the only medicinal cannabis company listed on the ASX — with the capacity to commercially cultivate medicinal-grade cannabis in Colombia.
Canada, on the other hand, which last week legalised recreational pot (making it the first major western country to do so) is expected to be a US$6.5 billion industry by 2020, according to Canadian Imperial Bank of Commerce (CIBC).
These kinds of sales exceed the amount Canadians spend on alcoholic spirits, and approach wine sales levels.
CIBC predicts that in the next two years, Canadians will consume 800,000 kilograms of cannabis, the vast majority of which will be for recreational use.
CPH’s leverage to this budding Canadian market gives it a clear advantage, especially in terms of capacity for cultivation.
Other ASX pot-stocks with a stake in, or leverage to, Canadian cannabis include Roto-Gro International (ASX:RGI), The Hydroponics Company (ASX: THC), AusCann (ASX:AC8), and MMJ Phytotech (ASX: MMJ).
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
